America’s global leadership in biopharmaceutical manufacturing
By Nicole Longo | June 4, 2020
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other...
Read More
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
By Sarah Sutton | February 12, 2020
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.
Read More
What you need to know about H.R. 3
By Tom Wilbur | December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...
Read More
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
By Nicole Longo | December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...
Read More
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
By Tom Wilbur | October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.
Read More
Pelosi’s radical plan leaves lung cancer patients behind
By Tom Wilbur | October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...
Read More
Pelosi’s radical plan would leave Alzheimer’s patients behind
By Tom Wilbur | October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
By Tom Wilbur | October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
